Therapy-related myelodysplastic syndromes are possible complications in patients treated for previous hematologic malignancies. Therapeutic strategies in these type of disorders are still not well defined: azacitidine has been recently approved for the treatment of higher risk myelodysplastic syndromes, but few data are published relating possible efficacy in therapy-related dysplastic disorders. We reported here 4 patients treated with azacitidine for therapy related dysplasia after chemotherapy for non-Hodgkin lymphoma.
5'-Azacitidine for therapy-related myelodysplastic syndromes after non-Hodgkin lymphoma treatment / Breccia, M; Salaroli, A; Loglisci, G; Martelli, Maurizio; D'Elia, Gm; Nanni, M; Mauro, Francesca Romana; Alimena, Giuliana. - In: LEUKEMIA RESEARCH. - ISSN 0145-2126. - STAMPA. - 35:(2011), pp. 1409-1411. [10.1016/j.leukres.2011.05.030]
5'-Azacitidine for therapy-related myelodysplastic syndromes after non-Hodgkin lymphoma treatment.
Breccia M;MARTELLI, Maurizio;MAURO, Francesca Romana;ALIMENA, Giuliana
2011
Abstract
Therapy-related myelodysplastic syndromes are possible complications in patients treated for previous hematologic malignancies. Therapeutic strategies in these type of disorders are still not well defined: azacitidine has been recently approved for the treatment of higher risk myelodysplastic syndromes, but few data are published relating possible efficacy in therapy-related dysplastic disorders. We reported here 4 patients treated with azacitidine for therapy related dysplasia after chemotherapy for non-Hodgkin lymphoma.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
